Senate Finance Committee Staff Report On GlaxoSmithKline and The Diabetes Drug Avandia – Links to Original Documents

By Thomas Sullivan Last updated May 4, 2018

[#Beginning of Shooting Data Section] Nikon D2Xs Focal Length: 200mm Optimize Image: Color Mode: Mode II (Adobe RGB) Long Exposure NR: Off High ISO NR: On (Normal) 2007/01/24 10:19:51.8 Exposure Mode: Manual White Balance: Color Temp. (2800 K) Tone Comp.: Auto RAW (12-bit) Metering Mode: Multi-Pattern AF Mode: AF-S Hue Adjustment: 0° 1/125 sec - F/3.2 Flash Sync Mode: Not Attached Saturation: Normal Color Exposure Comp.: 0 EV Sharpening: Normal Lens: VR 70-200mm F/2.8 G Sensitivity: ISO 800 Image Comment: U.S. Senate Photo by Frank Fey [#End of Shooting Data Section]

Today the New York Times published some of the findings of a report conducted by the Senate Finance Committee Staff on the Diabetes Drug Avandia that was scheduled to be released on Monday.

The report is critical of GlaxoSmithKline’s internal procedures. It is also critical of the FDA’s procedures on adjudicating drug safety issues.

We will be providing a full analysis in the coming days.

Subsequently the report and supporting documents were released today by the Senate Finance Committee.

Senators Urge FDA to Crack Down on Social Media Prescription…

Apr 23, 2024

Bipartisan Group of Attorneys General Send Letter to…

Apr 17, 2024

Senate Finance Committee Looking Into Health Insurance…

Apr 10, 2024

Bellow are the links to the relevant documents:

Grassley, Baucus release committee report on Avandia 2/20/10

Full Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia 2/20/10

Senators’ letter to the FDA with attachments 2/20/10